Retatrutide for the treatment of obesity: A phase 2, randomized, double-blind, placebo-controlled trial Summary: A Phase 2 clinical trial by Jastreboff et al
Theyre typically intended for daily use, often with or without food, depending on the brand
This reflects the medications dual-action mechanism, but the goal is the same: let your body acclimate
"What fundamentally differentiates Calibrate from anyone else on the internet is that we really believe that to increase access to obesity treatment, you have to find a way to use GLP-1s across a population cost effectively, which means some people are on and off of them
GHK-Cu's attenuation of p38 MAPK signaling offers a new paradigm to combat chemoresistance in cancer patients
People with Wilson's disease or copper metabolism disorders should avoid GHK-Cu entirely